PATENT CLAIM ANALYSIS

Application Number: 16049898
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["514", "019600"]

Abstract:
There is provided a method of treating a myeloid leukemia. The method includes the step of administering to a subject in need thereof a therapeutically effective amount of a CXCR4-antagonistic peptide and a therapeutically effective amount of a chemotherapeutic agent.

Claim (Index 2):
The method of  claim 1 , wherein said CXCR4-antagonistic peptide is administered to said subject in a daily amount between 0.1 to 10 mg per kg of body weight.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 95.0
- Lexical Diversity: 1.5
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13360751', '12520699', '13378061', '12520811', '14395842']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8010149264051595
- 35 USC 102 Novelty (BERT): 0.5425513805019335
- Combined Prediction Score: 0.7751685718148369
- Mean Citation Score: 381.915832
- Max Citation Score: 400.68774
- Similarity Product: 254.1354050379896

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test